Absolutely not. He is piggy-backing on the landmark work by other groups; he just re-applied it to the eye organ. The doxycyclin-based approach which this kind

Absolutely not. He is piggy-backing on the landmark work by other groups; he just re-applied it to the eye organ. The doxycyclin-based approach which this kind of studies are using can't be translated for clinical application in humans and in general partial reprogramming carries the risk of teratomas. So contrary to that tweet, it won't be ready for the clinic for years, decades, maybe never.